ArticleProstate cancer and prostatic diseases2025
Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality.
Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Validation of diagnostic artificial intelligence models for prostate pathology in a Middle Eastern cohort.Virchows Archiv : an international journal of pathology · 2026Article
- Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis.World journal of urology · 2026Article
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations.Prostate cancer and prostatic diseases · 2026Review
- Association Between Physical Activity and Mortality in Men with or at Risk of Prostate Cancer: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Cancer-Specific Mortality in Rare Histological Subtypes of Prostate Cancer: Radical Prostatectomy Versus Radiation Therapy.Annals of surgical oncology · 2026Article
- Metformin in prostate cancer: a context-dependent antitumour strategy driven by metabolic vulnerability and signalling network.Discover oncology · 2026Review
- HPV-positive cancers at uncommon sites: a narrative review.Oncology reviews · 2026Review
- Tumor behavior disparities in all-cause and cause-specific mortality among patients with central nervous system tumors.Scientific reports · 2025Article
- Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis.International urology and nephrology · 2025Article
- Contemporary rates and predictors of prolonged hospital stay after radical cystectomy: a population-based analysis.World journal of urology · 2025Article
- Life expectancy in rare histological prostate cancer subtypes.International journal of cancer · 2025Article
- Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review.Biomedicines · 2025Review
- Secondary signet ring cell carcinoma of the prostate: a case report.Journal of surgical case reports · 2025Article
- The Safety and Efficacy of Vascular-Targeted Photodynamic Therapy in Low-Risk Prostate Cancer.Cancers · 2025Article
- Pathologic characteristics and management strategies for two categories of prostate cancer patients with low prostate-specific antigen undergoing radical prostatectomy.Translational andrology and urology · 2025Article
- Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival.Annals of surgical oncology · 2024Article
- Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.
methodsUsing the Surveillance, Epidemiology, and End Results database (2004-2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models.
resultsOf 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients.
conclusionsCompared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.